RLMD Relmada Therapeutics Inc
Price (delayed)
$0.3031
Market cap
$10.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.65
Enterprise value
$6.2M
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed
Highlights
Relmada Therapeutics's net income has increased by 19% YoY and by 8% QoQ
The EPS has grown by 19% YoY and by 7% from the previous quarter
RLMD's equity has plunged by 58% YoY and by 25% from the previous quarter
The quick ratio has contracted by 45% YoY and by 35% from the previous quarter
Key stats
What are the main financial stats of RLMD
Market
Valuations
Earnings
Shares outstanding
33.19M
Market cap
$10.06M
Enterprise value
$6.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$83.89M
Net income
-$79.98M
EBIT
-$79.98M
EBITDA
-$79.98M
Free cash flow
-$51.76M
Per share
Balance sheet
Liquidity
EPS
-$2.65
EPS diluted
-$2.65
Free cash flow per share
-$1.72
Book value per share
$1.18
Revenue per share
$0
TBVPS
$1.52
Total assets
$45.82M
Total liabilities
$10.3M
Debt
$0
Equity
$35.52M
Working capital
$35.5M
Debt to equity
0
Current ratio
4.45
Quick ratio
4.36
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-124.5%
Return on equity
-147.6%
Return on invested capital
-153.9%
Return on capital employed
-225.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLMD stock price
How has the Relmada Therapeutics stock price performed over time
Intraday
10.78%
1 week
-1.24%
1 month
16.58%
1 year
-93.86%
YTD
-41.71%
QTD
12.26%
Financial performance
How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.89M
Net income
-$79.98M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's operating income has increased by 19% YoY and by 8% from the previous quarter
Relmada Therapeutics's net income has increased by 19% YoY and by 8% QoQ
Growth
What is Relmada Therapeutics's growth rate over time
Valuation
What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
0.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 19% YoY and by 7% from the previous quarter
The P/B is 93% less than the 5-year quarterly average of 3.1 and 85% less than the last 4 quarters average of 1.5
RLMD's equity has plunged by 58% YoY and by 25% from the previous quarter
Efficiency
How efficient is Relmada Therapeutics business performance
Relmada Therapeutics's return on equity has shrunk by 58% YoY and by 14% QoQ
The ROA has declined by 46% year-on-year and by 11% since the previous quarter
RLMD's return on invested capital is down by 44% year-on-year and by 15% since the previous quarter
Dividends
What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLMD.
Financial health
How did Relmada Therapeutics financials performed over time
Relmada Therapeutics's total assets has shrunk by 53% YoY and by 18% QoQ
The quick ratio has contracted by 45% YoY and by 35% from the previous quarter
RLMD's debt is 100% smaller than its equity
RLMD's equity has plunged by 58% YoY and by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.